Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis

BACKGROUND: Recently, chimeric antigen receptor-modified (CAR) T cell therapy for hematological malignancies has shown clinical efficacy. Hundreds of clinical trials have been registered and lots of studies have shown hematologic toxic effects were very common. The main purpose of this review is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Wenjing, Li, Chenggong, Zhang, Yinqiang, Du, Mengyi, Kou, Haiming, Lu, Cong, Mei, Heng, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785493/
https://www.ncbi.nlm.nih.gov/pubmed/35073859
http://dx.doi.org/10.1186/s12885-021-09102-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785493/
https://www.ncbi.nlm.nih.gov/pubmed/35073859
http://dx.doi.org/10.1186/s12885-021-09102-x

Ejemplares similares